Neuronetics Osake

Neuronetics Velat/EBITDA

Kokonaisvelka suhteessa EBITDA:han yhtiöstä Neuronetics (STIM) 22.8.2026 päivämäärällä on −2,15. Edellisenä vuonna Kokonaisvelka suhteessa EBITDA:han oli −1,51 — muutos 42,11 % (matalampi).

Velat/EBITDA

−2,15

YoY

42,11%

Viimeksi päivitetty:

Kokonaisvelka suhteessa EBITDA:han yhtiöstä Neuronetics on 2026 −2,15 . Kokonaisvelka suhteessa EBITDA:han yhtiöstä Neuronetics oli 2025 −1,51 . Se laskee 42,11% matalampi edelliseen vuoteen verrattuna.

Neuronetics Velat/EBITDA historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

Velat/EBITDA
Date
Velat/EBITDA
1.1.2018
−1,49 USD
1.1.2019
−1,10 USD
1.1.2020
−1,51 USD
1.1.2021
−1,27 USD
1.1.2022
−1,07 USD
1.1.2023
−1,94 USD
1.1.2024
−1,51 USD
1.1.2025
−2,15 USD
Neuronetics Velat/EBITDA historia
VUOSIVelat/EBITDAYoY
−2,15+42,11%
−1,51−22,00%
−1,94+81,13%
−1,07−15,42%
−1,27−16,07%
−1,51+37,10%
−1,10−26,12%
−1,49−34,21%
−2,26+2,62%
−2,21
Access this data via the Eulerpool API

Neuronetics Osakeanalyysi

Mitä Neuronetics tekee? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Neuronetics osakkeesta

Yhtiön Neuronetics Kokonaisvelka suhteessa EBITDA:han on −2,15 vuonna 2026.

Kokonaisvelka suhteessa EBITDA:han yhtiöstä Neuronetics muuttui arvosta −1,51 arvoon −2,15, mikä edustaa 42,11 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää Kokonaisvelka suhteessa EBITDA:han Neuronetics:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Velka/EBITDA mittaa kokonaisvelkaa suhteessa tulokseen ennen korkoja, veroja ja poistoja. Se osoittaa, kuinka monella vuodella kaikki velat voitaisiin maksaa takaisin EBITDA:sta.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata Kokonaisvelka suhteessa EBITDA:han:n Neuronetics alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Vipuvaikutus — Neuronetics

Kaikki tunnusluvut — Neuronetics